276 related articles for article (PubMed ID: 32726914)
1. Bitter Melon (
Sur S; Ray RB
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32726914
[TBL] [Abstract][Full Text] [Related]
2. Diverse roles of bitter melon (
Sur S; Ray RB
J Cancer Metastasis Treat; 2021; 7():. PubMed ID: 34765739
[TBL] [Abstract][Full Text] [Related]
3. Bitter melon: a panacea for inflammation and cancer.
Dandawate PR; Subramaniam D; Padhye SB; Anant S
Chin J Nat Med; 2016 Feb; 14(2):81-100. PubMed ID: 26968675
[TBL] [Abstract][Full Text] [Related]
4.
Bortolotti M; Mercatelli D; Polito L
Front Pharmacol; 2019; 10():486. PubMed ID: 31139079
[No Abstract] [Full Text] [Related]
5. Effects of dietary wild bitter melon (Momordica charantia var. abbreviate Ser.) extract on glucose and lipid metabolism in HFD/STZ-induced type 2 diabetic rats.
Sun K; Ding M; Fu C; Li P; Li T; Fang L; Xu J; Zhao Y
J Ethnopharmacol; 2023 Apr; 306():116154. PubMed ID: 36634725
[TBL] [Abstract][Full Text] [Related]
6. Emerging Antitumor Activities of the Bitter Melon (Momordica charantia).
Fang EF; Froetscher L; Scheibye-Knudsen M; Bohr VA; Wong JH; Ng TB
Curr Protein Pept Sci; 2019; 20(3):296-301. PubMed ID: 29932035
[TBL] [Abstract][Full Text] [Related]
7. Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.
Raina K; Kumar D; Agarwal R
Semin Cancer Biol; 2016 Oct; 40-41():116-129. PubMed ID: 27452666
[TBL] [Abstract][Full Text] [Related]
8. Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade.
Yung MM; Ross FA; Hardie DG; Leung TH; Zhan J; Ngan HY; Chan DW
Integr Cancer Ther; 2016 Sep; 15(3):376-89. PubMed ID: 26487740
[TBL] [Abstract][Full Text] [Related]
9. Draft genome sequence of bitter gourd (Momordica charantia), a vegetable and medicinal plant in tropical and subtropical regions.
Urasaki N; Takagi H; Natsume S; Uemura A; Taniai N; Miyagi N; Fukushima M; Suzuki S; Tarora K; Tamaki M; Sakamoto M; Terauchi R; Matsumura H
DNA Res; 2017 Feb; 24(1):51-58. PubMed ID: 28028039
[TBL] [Abstract][Full Text] [Related]
10. Identification of chemotypes in bitter melon by metabolomics: a plant with potential benefit for management of diabetes in traditional Chinese medicine.
Zhou S; Allard PM; Wolfrum C; Ke C; Tang C; Ye Y; Wolfender JL
Metabolomics; 2019 Jul; 15(8):104. PubMed ID: 31321563
[TBL] [Abstract][Full Text] [Related]
11.
Çiçek SS
Front Pharmacol; 2022; 13():904643. PubMed ID: 35656300
[No Abstract] [Full Text] [Related]
12. Quantitative determination of cucurbitane-type triterpenes and triterpene glycosides in dietary supplements containing bitter melon (Momordica charantia) by HPLC-MS/MS.
Ma J; Krynitsky AJ; Grundel E; Rader JI
J AOAC Int; 2012; 95(6):1597-608. PubMed ID: 23451374
[TBL] [Abstract][Full Text] [Related]
13. Bitter melon: antagonist to cancer.
Nerurkar P; Ray RB
Pharm Res; 2010 Jun; 27(6):1049-53. PubMed ID: 20198408
[TBL] [Abstract][Full Text] [Related]
14. Antioxidant properties and quantitative UPLC-MS analysis of phenolic compounds from extracts of fenugreek (Trigonella foenum-graecum) seeds and bitter melon (Momordica charantia) fruit.
Kenny O; Smyth TJ; Hewage CM; Brunton NP
Food Chem; 2013 Dec; 141(4):4295-302. PubMed ID: 23993618
[TBL] [Abstract][Full Text] [Related]
15. Metabolite profiling and in vitro biological activities of two commercial bitter melon (Momordica charantia Linn.) cultivars.
Perez JL; Jayaprakasha GK; Patil BS
Food Chem; 2019 Aug; 288():178-186. PubMed ID: 30902279
[TBL] [Abstract][Full Text] [Related]
16. New insights into the bioactive polysaccharides, proteins, and triterpenoids isolated from bitter melon (Momordica charantia) and their relevance for nutraceutical and food application: A review.
Bora AFM; Kouame KJE; Li X; Liu L; Pan Y
Int J Biol Macromol; 2023 Mar; 231():123173. PubMed ID: 36642359
[TBL] [Abstract][Full Text] [Related]
17. Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus.
Kim SK; Jung J; Jung JH; Yoon N; Kang SS; Roh GS; Hahm JR
Complement Ther Med; 2020 Aug; 52():102524. PubMed ID: 32951763
[TBL] [Abstract][Full Text] [Related]
18. MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis.
Chan DW; Yung MM; Chan YS; Xuan Y; Yang H; Xu D; Zhan JB; Chan KK; Ng TB; Ngan HY
Pharmacol Res; 2020 Nov; 161():105157. PubMed ID: 32814169
[TBL] [Abstract][Full Text] [Related]
19. Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats.
Shih CC; Lin CH; Lin WL; Wu JB
J Ethnopharmacol; 2009 May; 123(1):82-90. PubMed ID: 19429344
[TBL] [Abstract][Full Text] [Related]
20. First Report of Pseudoperonospora cubensis Causing Downy Mildew on Momordica balsamina and M. charantia in North Carolina.
Wallace E; Adams M; Ivors K; Ojiambo PS; Quesada-Ocampo LM
Plant Dis; 2014 Sep; 98(9):1279. PubMed ID: 30699625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
